Drugs /

kin-2787

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for kin-2787

Kin-2787 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating kin-2787, 1 is phase 1 (1 open).

BRAF Mutation is the most frequent biomarker inclusion criterion for kin-2787 clinical trials.

Malignant solid tumor is the most common disease being investigated in kin-2787 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Kin-2787
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating kin-2787 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
kin-2787 raf inhibitor
Drug Target(s) [2]:
ARAF, BRAF, RAF1

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.